A Single-dose, Open, Randomized, Crossover Investigation of Age, Gender, Food-effect and Proton-pump Interaction on the Pharmacokinetics of GSK1325756 in Healthy Adult Subjects and a Single-dose, Double Blind, Parallel-group, Placebo- Controlled Investigation of the Pharmacokinetics of GSK1325756.
Latest Information Update: 20 Sep 2023
At a glance
- Drugs Danirixin (Primary) ; Omeprazole
- Indications Chronic obstructive pulmonary disease; Gastro-oesophageal reflux; NSAID-induced gastrointestinal damage
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 05 Oct 2010 New trial record